Showing 1031-1040 of 18563 results for "".
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
https://reachmd.com/clinical-practice/nephrology/optimizing-igan-care-sparsentans-role-amid-the-latest-kdigo-guideline-updates/30044/Examine updated KDIGO 2025 IgAN guidelines and sparsentan’s role in managing proteinuria and slowing kidney function decline.Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
https://reachmd.com/programs/cme/tbd/37674/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Seltorexant vs Quetiapine XR in MDD With Insomnia: A 26-Week Phase 3 Comparison
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/seltorexant-vs-quetiapine-xr-in-mdd-with-insomnia-a-26-week-phase-3-comparison/37644/Compare efficacy, safety, and tolerability of adjunctive seltorexant versus quetiapine XR in MDD patients with insomnia symptoms.Menin Inhibitors: Biologic and Clinical Rationale
https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
https://reachmd.com/programs/heart-matters/early-initiation-of-acoramidis-in-attr-cm-importance-and-long-term-impacts/35757/Acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), was studied in an open-label extension of the ATTRibute-CM trial to determine whether its early and sustained use improves clinical outcomes. Discover acoramidis’ long-term impacts on all-cause mortality and/or first cardiovTreating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
https://reachmd.com/programs/project-oncology/treating-rr-classic-hodgkin-lymphoma-ipilimumab-and-other-approaches/26405/Read about the efficacy and safety of ipilimumab as a standalone treatment for relapsed or refractory classic Hodgkin lymphoma.Investigating the Circulation of Counterfeit COVID-19 Medications
https://reachmd.com/programs/covid-19-frontlines/investigating-the-circulation-of-counterfeit-covid-19-medications/11624/The worldwide shortfall of drugs and drug supplies has fueled an illicit trade market for illegal pharmaceuticals and medical items.Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19
https://reachmd.com/programs/the-drug-report/renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-covid-19/11416/Do the benefits of continuing the use of RAAS inhibitors in patients outweigh the risks due to the inhibitors’ potential link to COVID-19 severity?The Pathologist Perspective: Identifying Systemic Mastocytosis in the Community
https://reachmd.com/programs/cme/the-pathologist-perspective-identifying-systemic-mastocytosis-in-the-community/32207/Explore 4 case-based episodes for insights on the pathologist’s role in the identification and diagnosis of systemic mastocytosis in the community.Revolutionizing Aesthetic Medicine and Dermatology with Artificial Intelligence
https://modernaesthetics.com/ma-issues-index/2025-mar-apr/revolutionizing-aesthetic-medicine-and-dermatology-with-artificial-intelligence/36064/This article explores the possibilities of AI and how it can be ethically utilized to enhance aesthetic medicine and marketing to grow one’s practice to its maximum potential.